KP104
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Key Facts
About Kira Pharmaceuticals
Kira Pharmaceuticals is a private, clinical-stage biotech founded in 2018 and headquartered in Cambridge, Massachusetts, USA. The company is focused exclusively on developing transformative therapies for complement-mediated diseases, leveraging its LOGIC platform for drug discovery and optimization. Its lead asset, KP104, is a bifunctional biologic in Phase 2 trials for multiple indications, including PNH, IgAN, and C3G, positioning the company in the rapidly evolving complement therapeutics space. With a deep pipeline of nine assets and a team combining complement biology expertise with seasoned drug development, Kira aims to deliver first-in-class and best-in-class treatments.
View full company profileAbout Kira Pharmaceuticals
Kira Pharmaceuticals is a private, clinical-stage biotech founded in 2018 and headquartered in Cambridge, Massachusetts, USA. The company is focused exclusively on developing transformative therapies for complement-mediated diseases, leveraging its LOGIC platform for drug discovery and optimization. Its lead asset, KP104, is a bifunctional biologic in Phase 2 trials for multiple indications, including PNH, IgAN, and C3G, positioning the company in the rapidly evolving complement therapeutics space. With a deep pipeline of nine assets and a team combining complement biology expertise with seasoned drug development, Kira aims to deliver first-in-class and best-in-class treatments.
View full company profileAbout Kira Pharmaceuticals
Kira Pharmaceuticals is a private, clinical-stage biotech founded in 2018 and headquartered in Cambridge, Massachusetts, USA. The company is focused exclusively on developing transformative therapies for complement-mediated diseases, leveraging its LOGIC platform for drug discovery and optimization. Its lead asset, KP104, is a bifunctional biologic in Phase 2 trials for multiple indications, including PNH, IgAN, and C3G, positioning the company in the rapidly evolving complement therapeutics space. With a deep pipeline of nine assets and a team combining complement biology expertise with seasoned drug development, Kira aims to deliver first-in-class and best-in-class treatments.
View full company profileTherapeutic Areas
Other Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
| Drug | Company | Phase |
|---|---|---|
| OMS906 | Omeros | Phase 2 |
| Empaveli (pegcetacoplan) | bioRASI | Approved |
| EMPAVELI Injector | Enable Injections | Approved |
| Ruxoprubart (NM8074) | NovelMed Therapeutics | Phase 2 |
| Fabhalta® (iptacopan) | Novartis | Approved |
| NS-580/NM-8074 | Nippon Shinyaku | Phase 2 |
| Pegcetacoplan (Systemic) | Apellis Pharmaceuticals | Approved |